Skip to Main Content

Paper Details

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia.
Blood Adv
3
2024
AML, AMLs, AZA, BCL-2, CD123, CD123-positive AML, MDS, MLFS, TAG, TAG-AZA-VEN, TAG-exposed cells, TP53, TP53 mutations, TP53-mutated disease, Tagraxofusp, VEN, acute myeloid leukemia, acute myeloid leukemias, azacitidine, blastic plasmacytoid dendritic cell neoplasm, interleukin-3 receptor, myelodysplastic syndrome, patients, recombinant interleukin-3, tagraxofusp, truncated diphtheria toxin, venetoclax
Author NameAffiliation
Daniel J DeAngeloDana-Farber Cancer Institute
Marlise R LuskinDana-Farber Cancer Institute
Richard M StoneDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
Donna NeubergDana-Farber Cancer Institute
  • 1 - 5

Datasets

Release 1.2